Orthocell Ltd Total Liabilities

Latest as of June 2025: AU$20.67 Million AUD ≈ $14.62 Million USD

Orthocell Ltd total liabilities. Based on the latest financial reports, Orthocell Ltd (OCC) has total liabilities worth AU$20.67 Million AUD (≈ $14.62 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OCC asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Orthocell Ltd (2010–2025)

Total liabilities of Orthocell Ltd from 2010 to 2025. This chart illustrates how Orthocell Ltd's total liabilities have evolved over time, based on quarterly financial data.

Orthocell Ltd Competitors by Total Liabilities

The table below lists competitors of Orthocell Ltd ranked by their total liabilities.

Company Country Total Liabilities
Besiktas Futbol Yatirimlari Sanayi ve Ticaret AS
IS:BJKAS
Turkey TL23.00 Billion
Minerva Neurosciences Inc
NASDAQ:NERV
USA $348.04 Million
Humanica Public Company Limited
BK:HUMAN
Thailand ฿553.69 Million
San Lien Technology
TWO:5493
Taiwan NT$2.82 Billion
Noroo Paint
KO:090350
Korea ₩343.45 Billion
Graphite One Inc
V:GPH
Canada CA$3.66 Million
Nelly Group AB
ST:NELLY
Sweden Skr547.40 Million
Avaco Co. Ltd
KQ:083930
Korea ₩168.17 Billion

Liability Composition Analysis (2010–2025)

This chart breaks down Orthocell Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Orthocell Ltd (OCC) total assets.

Liquidity & Leverage Metrics

Orthocell Ltd Total Liabilities Ratios Explained

Orthocell Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 4.97 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 4.47 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.59 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Orthocell Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Orthocell Ltd (2010–2025)

The table below shows the annual total liabilities of Orthocell Ltd from 2010 to 2025.

Year Total Liabilities Change
2025-06-30 AU$20.67 Million
≈ $14.62 Million
-6.40%
2024-06-30 AU$22.08 Million
≈ $15.62 Million
-5.86%
2023-06-30 AU$23.46 Million
≈ $16.60 Million
-16.20%
2022-06-30 AU$27.99 Million
≈ $19.81 Million
+1039.68%
2021-06-30 AU$2.46 Million
≈ $1.74 Million
+8.34%
2020-06-30 AU$2.27 Million
≈ $1.60 Million
-21.10%
2019-06-30 AU$2.87 Million
≈ $2.03 Million
+0.54%
2018-06-30 AU$2.86 Million
≈ $2.02 Million
+16.81%
2017-06-30 AU$2.45 Million
≈ $1.73 Million
+9.77%
2016-06-30 AU$2.23 Million
≈ $1.58 Million
+3.54%
2015-06-30 AU$2.15 Million
≈ $1.52 Million
-57.48%
2014-06-30 AU$5.06 Million
≈ $3.58 Million
+636.52%
2013-06-30 AU$687.24K
≈ $486.27K
+100.36%
2011-06-30 AU$343.00K
≈ $242.69K
+67.32%
2010-06-30 AU$205.00K
≈ $145.05K
--

About Orthocell Ltd

AU:OCC Australia Biotechnology
Market Cap
$109.42 Million
AU$154.65 Million AUD
Market Cap Rank
#18643 Global
#577 in Australia
Share Price
AU$0.57
Change (1 day)
+0.00%
52-Week Range
AU$0.50 - AU$1.15
All Time High
AU$1.75
About

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membr… Read more